Recognizing that radioligand therapy is most effective early when tumors are "target-rich," new clinical trials accelerate dosing and intensity upfront. This strategy aims to deliver the most significant therapeutic blow before diminishing returns set in as the tumor responds and the target is lost.

The effectiveness of radioligand therapy is counterintuitive: as tumors shrink and PSMA binding sites decrease, less radiation is delivered to the cancer. The VISION trial showed the first two doses delivered more radiation to the tumor than the subsequent four, questioning the value of a fixed, prolonged treatment schedule.

Unlike traditional chemotherapy, radioligand therapy's toxicity may be inversely correlated with tumor volume. In low-burden disease, fewer cancer cells act as a 'sink' for the drug, potentially leading to higher radiation exposure and side effects in healthy, PSMA-expressing tissues like salivary glands.

While PSMA PET scans are more sensitive, they create a clinical dilemma because pivotal trials defining treatment efficacy were based on conventional imaging (CT/bone scans). This forces oncologists to either re-image patients with older technology to match trial criteria or make treatment decisions based on PET data that lacks a clear evidence-based framework for response assessment.

Early in treatment, tumors are "target-rich" with high PSMA expression, creating an ideal window for radioligand therapy. Citing data from the VISION trial, new clinical trials are being designed to accelerate dosing and intensity upfront to maximize impact, then de-escalate as the target diminishes.

The future of advanced prostate cancer treatment is shifting towards therapies that target cell surface markers. This new era will be defined by a growing arsenal of radioligands, T-cell engaging bispecific antibodies (BiTEs), and antibody-drug conjugates (ADCs) aimed at targets like PSMA, B7-H3, and HK2.

Unlike traditional CT scans, PSMA-PET scans visualize the biological heterogeneity of prostate cancer, showing which lesions are target-rich and which are not. While insightful, this "shines a flashlight" on the problem, creating new clinical challenges, such as how to manage a patient whose disease largely disappears except for two resistant lesions.

Even if most of a patient's cancer is PSMA-avid, the presence of small liver lesions that are *not* PSMA-avid is a major red flag. This can indicate a more aggressive, PSMA-negative biology that won't respond to PSMA-targeted therapy and may instead require alternative treatments like chemotherapy, complicating patient selection.

Unlike chemotherapy, radioligand therapy's effectiveness wanes as tumors shrink. With less PSMA target for the drug to bind to, less radiation is delivered to the cancer. This physical reality supports "adaptive dosing"—stopping treatment in high-responders to spare healthy tissue and resume later if needed.